Background Targeting CTLA-4 is a recent strategic approach in cancer control: blocking
CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T …

Introduction Advances in immunotherapy have transformed the management of metastatic
melanoma and generated encouraging results in the treatment of other malignancies …

Objective Few data are published on the long-term follow-up of ipilimumab-induced
hypophysitis, a cytotoxic T-lymphocyte antigen 4 antibody. We characterized hypophysitis in …

Immune checkpoint inhibitors have recently become a cornerstone for the treatment of
different advanced cancers. These drugs, represented mainly by monoclonal antibodies anti …

Hypophysitis is a rare condition characterised by inflammation of the pituitary gland, usually
resulting in hypopituitarism and pituitary enlargement. Pituitary inflammation can occur as a …

In recent years, the development of immunotherapy has constituted a revolution in the
therapy for many cancers, with a specific toxicity profile including endocrine immune-related …

Abstract 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18
F-FDG PET/CT) is increasingly used in patients with advanced melanoma. Immune …

The FSH molecular mechanism of action is best recognized for its stimulation of the adenylyl
cyclase/cAMP pathway via activation of a G protein. Recently, links between cAMP …

In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer
therapy and these drugs have already become essential for the treatment of various non …

Ipilimumab is a monoclonal antibody against the inhibitory CTLA-4 receptor expressed on T
cells. It provokes an upregulation of the immune system. This substance was approved by …